Literature DB >> 10227778

Lipoprotein (a) immunapheresis in the treatment of familial lipoprotein (a) hyperlipoproteinemia in a patient with coronary heart disease.

R Straube1, H Kingreen.   

Abstract

This paper reports 2 years' experience with lipoprotein (a) (Lp[a]) immunapheresis which was successfully handled on a now 40-year-old patient with familial Lp(a) hyperlipoproteinemia inducing severe coronary heart disease with 2 myocardial infarctions and diffuse coronary sclerosis. Continued treatment by Lp(a) immunabsorption with specific sheep antibodies reduced stenosis in coronary vessels more than 50% and stopped the progression of coronary heart disease. A special apheresis technique and the results of continued absorption effects are described.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10227778     DOI: 10.1111/j.1744-9987.1998.tb00112.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  1 in total

1.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.